SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia. Biol. Psychiatry 2000; 47: 821.
  • 2
    Ross BM. Phospholipid and eicosanoid signaling disturbances in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 2003; 69: 407412.
  • 3
    Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L. Oxidative stress involvement in schizophrenia pathophysiology. Encephale 2006; 32: 244252.
  • 4
    Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001; 15: 287310.
  • 5
    Du Bois TM, Deng C, Huang XF. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005; 29: 878888.
  • 6
    Dietrich-Muszalska A, Olas B. Isoprostanes as indicators of oxidative stress in schizophrenia. World J. Biol. Psychiatry 2009; 10: 2733.
  • 7
    Horrobin DE, Glen AIM, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr. Res. 1994; 13: 195202.
  • 8
    Gama CS, Salvador M, Andreazza AC et al. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci. Lett. 2008; 433: 270273.
  • 9
    Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002; 58: 110.
  • 10
    Arvindakshan M, Sitasawad S, Debsikdar V et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry 2003; 53: 5664.
  • 11
    Mahadik SP, Mukherjee S, Scheffer R, Correnti EE, Mahadik JS. Elevated plasma lipid peroxidases at the onset of nonaffective psychosis. Biol. Psychiatry 1998; 43: 674679.
  • 12
    Peet M, Zhi JZ, Selvam K, Ramchand CN. Plasma TBARS levels in unmedicated chronic schizophrenic patients. Schizophr. Res. 1997; 24: 66.
  • 13
    Akyol O, Herken H, Zu E et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002; 26: 9951005.
  • 14
    Reddy R, Kelkar H, Mahadik SP et al. Free radicals and neurological signs in chronic schizophrenic patients. Biol. Psychiatry 1994; 35: 699700.
  • 15
    Gama CS, Salvador M, Andreazza AC, Kapczinski F, Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006; 30: 512515.
  • 16
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington DC, 1994.
  • 17
    Sheehan DV, Lecrubier Y, Sheenhan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998; 59: 2233.
  • 18
    Rice-Evans CA, Diplock AT, Symons MCR. Techniques in Free Radical Research. Elsevier, Amsterdam, 1991.
  • 19
    Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic. Biol. Med. 1999; 26: 12311237.
  • 20
    Bartosz G. Total antioxidant capacity. Adv. Clin. Chem. 2003; 37: 219292.
  • 21
    Kay SR, Fisz-Bein A, Opler LA. The positive and negative syndrome scale (PANNS) for schizophrenia. Schizophr. Bull. 1987; 13: 261274.
  • 22
    Yao JK, van Kammen DP, Gurkis WJ. Correlation of fatty acid abnormalities with clinical measures in schizophrenia. Schizophr. Res. 1994; 11: 124.
  • 23
    Reddy RD, Yao JK. Environmental factors and membrane polyunsaturated fatty acids in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 2003; 69: 385391.
  • 24
    Bartosz G. Free radicals and the developmental pathology of schizophrenic burnout. [commentary] Integr. Psychiatry 1987; 5: 4344.
  • 25
    Van Kammen D, Yao JG, Goetz K. Polyunsaturated fatty acids, prostaglandins, and schizophrenia. Ann. N. Y. Acad. Sci. 1989; 559: 411423.
  • 26
    Mahadik SP, Evans DR. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr. Clin. North Am. 2003; 26: 85102.
  • 27
    Yao JK, Reddy R, McElhinnyl G, van Kammen DP. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr. Res. 1998; 32: 18.
  • 28
    Mukherjee S, Mahadik SP, Correnti EE et al. The antioxidant defenses system at the onset of psychosis. Biol. Psychiatry 1994; 35: 701.
  • 29
    Dietrich-Muszalska A, Olas B, Rabe-Jabłońska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005; 16: 386.
  • 30
    Khan NS, Das I. Oxidative stress and superoxide dismutase in schizophrenia. Biochem. Soc. Trans. 1997; 25: 418S.
  • 31
    Jeding I, Evans PJ, Akanmu D et al. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem. Pharmacol. 1995; 49: 359365.
  • 32
    Mahadik SP, Mukherjee S, Correnti EE, Scheffer R. Elevated levels of lipid peroxidation products in plasma of drug-naive patients at the onset of psychosis. Schizophr. Res. 1995; 15: 66.
  • 33
    Zhang XY, Tan YL, Cao LY et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006; 81: 291300.
  • 34
    Dietrich-Muszalska A. The impact of haloperidol on lipids peroxidation in human blood platelets and plasma at in vitro studies. Psychiatria i Psychologia Kliniczna 2004; 3: 150156.
  • 35
    Dietrich-Muszalska A. Evaluation of the effects of different concentrations of risperidone, corresponding to the drug doses used in treatment of schizophrenic patients, on lipid peroxidation in plasma and blood platelets at in vitro studies. Psychiatria i Psychologia Kliniczna 2004; 4: 215223.
  • 36
    Dietrich-Muszalska A. The impact of different concentrations of clozapine on changes of lipid peroxidation in human plasma –in vitro studies. Psychiatria i Psychologia Kliniczna 2005; 5: 1825.
  • 37
    Dietrich-Muszalska A, Olas B. Inhibitory effects of polyphenol compounds on lipid peroxidation caused by antipsychotics (haloperidol and amisulpride) in human plasma in vitro. World J. Biol. Psychiatry 2010; 11: 276281.
  • 38
    Xu H, Wang H, Zhuang L et al. Demonstration of an anti-oxidative stress mechanism of quetiapine. FEBS J. 2008; 275: 37183728.
  • 39
    Wang H, Xu H, Dyck LE, Li XM. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide (25–35)-induced oxidative stress and the ensuing apoptosis. J. Neurosci. Res. 2005; 81: 572580.
  • 40
    Cadet JL, Lohr JB, Jeste DV. Free radicals and tardive dyskinesia. Trends Neurosci. 1986; 9: 107108.
  • 41
    Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem. 1998; 71: 10021012.
  • 42
    Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005; 10: 79104.
  • 43
    Möller HJ. Novel antipsychotics in the long-term treatment of schizophrenia. World J. Biol. Psychiatry 2004; 5: 919.
  • 44
    Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J. Biol. Psychiatry 2005; 6: 132191.
  • 45
    Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term of schizophrenia. World J. Biol. Psychiatry 2006; 7: 540.
  • 46
    Kropp S, Kern V, Lange K et al. Oxidative stress during treatment with first- and second-generation antipsychotics. J. Neuropsychiatr. 2005; 17: 227231.
  • 47
    Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004; 49: 205209.